An Analysis Comparing Open Surgical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis  by Abela, R. et al.
Eur J Vasc Endovasc Surg (2009) 38, 666e675REVIEW
An Analysis Comparing Open Surgical and
Endovascular Treatment of Atherosclerotic Renal
Artery StenosisR. Abela a, S. Ivanova a, S. Lidder a, R. Morris b, G. Hamilton a,*a Royal Free Hospital, Department of Vascular Surgery, London, UK
b Department of Primary Care & Population Health, UCL, London, UK
Submitted 31 March 2009; accepted 10 August 2009







Renal function* Corresponding author. Tel.: þ44 2
E-mail address: g.hamilton@medsc
1078-5884/$36 ª 2009 European Socie
doi:10.1016/j.ejvs.2009.08.002Abstract Objective: Endovascular revascularization in atherosclerotic renal artery stenosis
(ARAS) has dominated during the last 15 years with surgery relegated mostly to back-up for
failed endovascular procedures. This study examines the available outcome evidence to deter-
mine what role open surgery should have in comparison to endovascular treatment in the
management of ARAS.
Method: Of 183 papers listed in PubMed, the USNLM and the Cochrane library, (1975e2004) 47,
dealing with outcomes of surgical and endovascular treatments (evidence levels 2b and 3) were
selected. Endovascular included 1750 patients in 16 prospective non-randomised (PNRT) and 5
retrospective (RET) studies. Surgical included 2314 patients in 4 PNRTs and 17 RETs. Outcome data
were subjected to meta-regression analysis weighted according to the inverse variance method.
Results: Meanmaximum ages were 79.4 yrs (SD 6.9) for surgical and 83.6 yrs (SD 3.8) for endovas-
cular studies. Primary technical success was similar. Endovascular patency declined by 0.26%/
month (95% CI: 0.04e0.48, pZ 0.03). Surgical studies showed greater improvement for hyperten-
sion control by 21% (95% CI: 9e33%, pZ 0.001) and for renal function by 34% (95% CI: 18e54%,
p < 0.001), as well as a higher creatinine reduction by 32 mmol/L (95% CI: 7e57 mmol/L,
p< 0.014). A higher excess surgical mortality, 3.1% (95% CI: 1.8e4.4%, p< 0.001) became insignif-
icant, 0.18% (95% CI: 0.7e1.1, pZ 0.70) when concomitant aortic surgery was excluded.
Conclusion: This data shows amarkedanddurable clinical benefit for surgery. Thesefindings ques-
tion the endovascular predominance in intervention in ARAS and highlight the need for a carefully
designed prospective randomised comparison to define the roles of endovascular and surgical
renal revascularization.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.077940500 ext 33072.
h.ucl.ac.uk (G. Hamilton).
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Revascularization in the management of atherosclerotic
renal artery stenosis has undergone a series of changes over
the past 4 decades.
After Goldblatt’s experiments in 19341and Leadbetter’s
report of the first cure of hypertension by surgical renal
artery revascularization in 19382 a direct causal relation-
ship was inferred. Since then the evolution of our knowl-
edge of the pathophysiology of renal artery stenosis and
modern medical treatment together with the asynchronous
developments in diagnosis, in surgery, and endovascular
techniques has taken management of the stenotic renal
artery through a surgical phase then an endovascular
phase. After recent input from key meta-analyses,3,4 the
role of endovascular revascularization is being assessed in
favour of or in tandem with medical management in trials
such as STAR, NITER, CORAL, RAVE and ASTRAL. Indeed the
trend seems to be to avoid intervention altogether however
though these studies include endovascular intervention in
the treatment process, they mostly fall short of investi-
gating the value and effect of restoring and maintaining
patency on their outcomes. Management of ARAS has
traditionally fallen within the realm of nephrologists with
largely technical input from surgeons and now mostly
endovascular interventionalists. Cardiologists have recently
questioned the role of ARAS in the management of CCF5,6
especially in the absence of left ventricular dysfunction and
coronary ischaemia. The US Renal Data Systems (2005)
reported a 2.1% incidence of ESRD (>9000 patients)
secondary to renal artery stenosis/occlusion with a 36.7%
first year mortality. The contribution of ARAS to CCF has yet
to be recognized and measured. Unfortunately, ARAS is not
an isolated causative lesion of a direct clinical manifesta-
tion as fibromuscular dysplasia may be of hypertension. It is
one contributing factor in the interplay of the hyperten-
sion, renal failure and congestive cardiac failure triad
within the background of the wider systemic manifestations
of atherosclerosis in our increasingly diabetic, hyper-
lipidaemic and aging population.
Despite advances in diagnostics, therapeutics and
management, the literature onARAS reflects a failure to reach
clear consensus on the indications for revascularization.
Changes in the decision process in ARAS management have
been largely driven by innovations, and trends in reporting and
treatment costs, with improvement of hypertension control
and renal function, or renal dialysis salvage being the com-
monest targets. Much of the published literature falls short of
a holistic long-term approach in terms of outcome and
patency, improved quality of life and survival benefit.
The current aversion to surgical revascularization is
understandable in this largely elderly and often unfit cohort
of patents but focused clinical evidence to support this
shift does not exist. Current management is based more on
clinical bias rather than evidence and the authors are
concerned that as a consequence, a minority of patients
that would benefit from surgical revascularization are not
being offered this treatment option. The major arguments
against surgical revascularization include the following:
1. The level of co-morbidity in these patients forbids the
use of anaesthetic dependent surgery.2. Outcome studies for surgical revascularizsation only
include younger fitter patients.
3. Endovascular and surgical procedures confer similarly
successful revascularization.
4. Endovascular and surgical procedures are similarly
successful in terms of outcome benefit.
5. The mortality linked to surgery is too high to justify it as
a treatment option.
In this review we chose to analyse the clinical evidence
that is available in the literature and have addressed the
issues of age, co-morbidity, technical success and patency,
survival, outcome benefit in hypertension and renal func-
tion and procedure-related mortality. We found a wide
heterogeneity in published papers in terms of indications
for intervention and in the types of outcomes and data
presented to depict success or otherwise of outcomes. This
has unfortunately limited the study to observational
retrospective and prospective non-randomised studies with
a complete absence of Level 1 data.Methods
Search Strategy: PubMed, the USNLM and the Cochrane
Library were searched for studies dealing with clinical
outcomes of surgical and endovascular revascularization for
ARAS. Search terms were sought in title, abstract and
keyword fields and included the following: atherosclerotic
renal artery stenosis, renal artery revascularization, renal
artery stenting and angioplasty, surgical revascularization,
renovascular hypertension, ischaemic nephropathy and
renal failure. 183 papers were initially retrieved in abstract
form and scanned. Abstract selection: abstracts dealing
with outcomes of endovascular and surgical revasculariza-
tion targeting improvement in hypertension control and
renal function were selected. Exclusion criteria included
other renal aetiologies, lack of an English language version
and other outcome targets. Remaining papers were then
retrieved and reference lists were examined for other
relevant publications.
Further exclusion criteria were applied: following
Nordmann’s recommendations in the 2003 Cochrane
review4 endovascular revascularization studies were
limited to stented studies. Studies selected were those in
which the data under examination could be extracted and
pooled (Table 1) and mainly fell into the category of
prospective and retrospective cohort studies. Fields
examined included: demographic data, co-morbidity,
length of follow-up, technical success, benefit to hyper-
tension and renal function, change in mean arterial blood
pressure (MAP), change in serum creatinine levels,
mortality, patency and 5-year survival. MAP was calculated
from basic systolic and diastolic pressure data in the
papers. Serum creatinine levels were converted to SI units
where other units were used. Creatinine clearance would
have been a better measure of renal function however this
was reported in very few of the papers and only used as an
outcome measure in 2 endovascular and 1 surgical papers.
Other consideration was given to analyzing the impact of
whether revascularization was unilateral or bilateral, the
relationship to pre-procedural degree of stenosis, the
Table 1 Papers included in this study: number of patients in each paper, mean age in years and % males. Where mean age was
not available, age range was included.
Surgical papers Endovascular papers
Author Year Patients Mean age % males Author Year Patients Mean age % males
Pechan BW9 1979 56 n/a 58.9 Rees CR10 1991 28 66 46.4
Novick AC11 1983 51 61 74.5 Raynaud A12 1994 18 58 55.6
Rieder CF13 1984 28 62 85.7 Dorros G14 1995 76 67 52.6
Chibaro EA15 1984 36 61 55.6 van de Ven PJ16 1995 24 66 54.2
Sicard GA17 1985 20 59 65.0 Iannone L18 1996 63 70 49.2
Novick AC19 1985 13 (56e74) 61.5 Rundback JH20 1996 20 70 55.0
Torsello G21 1990 326 58 67.8 Boisclair C22 1997 33 63 57.6
Stansby G23 1992 12 65 33.3 Harden PN24 1997 32 67 n/a
Bredenberg C25 1992 66 63 n/a White CJ26 1997 100 67 42.0
Libertino JA27 1992 97 62 46.4 Dorros G28 1998 145 67 50.3
Gill IS29 1993 13 59 76.9 Gross CM30 1998 30 66 63.3
Reilly J31 1994 48 66 31.3 Rundback JH32 1998 45 70 51.1
Chaikof E33 1994 50 66 74.0 Tuttle KR34 1998 129 71 48.8
Van Damme H35 1995 23 63 69.6 Henry M36 1999 210 68 66.2
Clair DG37 1995 43 68 58.1 Rocha-Singh KJ38 1999 140 67 41.9
Fergany A39 1995 171 62 54.9 Rodriguez-Lopez JA40 1999 108 72 59.2
Hallett J41 1995 304 68 71.7 Watson PS42 2000 33 72 51.5
Cambria RP43 1996 139 67 53.2 Lederman RJ44 2001 300 70 52.0
Steinbach F45 1997 220 60 57.7 Bush R46 2001 73 68 45.2
Cherr G47 2002 500 65 49.2 Henry M48 2003 56 66 57.1
Marone LK49 2004 96 70 48.8 Zhang Q50 2003 87 71 60.9
668 R. Abela et al.associationwithaortic diseaseandprocedures, and the salvage
from and progression to dialysis. Though all surgical and many
endovascular papers gave a detailed breakdown of the lesions
being treated, very few correlated this to outcomes.
Data were analysed using SPSS version 15 and Stata
version 10. Descriptive statistics refer to means of aggre-
gated outcomes. To assess the effect of aortic repair on
mortality and the benefits of the treatment modalities on
hypertension and renal function and patency analysis,
meta-regression analysis was carried out weighted accord-
ing to the inverse variance method, giving more weight to
larger studies. For outcomes represented as percentages
(e.g. mortality), the variance for a binomial distribution
was used, based on the percentage itself and the sample
size for the study. For means (MAP and creatinine), the
intention was to divide the standard deviation squared
divided by the sample size. However the standard deviation
was reported only for a minority of studies. For those
studies, the standard deviation value was similar between
the studies. Therefore in the meta-regression analysis,
weighting was done only according to the sample size.
In meta-regression, the intervention was the chief
independent variable, but where the post-procedural mean
MAP or creatinine was the dependent variable, pre-proce-
dural means were included as a covariate.
To investigate the impact of study size on the differ-
ences in outcome between surgical and endovascular
studies, an interaction term was added to the weighted
regression model. Study size was dichotomized as to
whether the studies had more or less than 40 patients. A
similar analysis of interaction with type of study compared
the effect in prospective non-randomised studies with
retrospective studies.Little evidence of interaction was found for type of
intervention either with size or type of study. The only
evidence of interaction was for improvement of hyperten-
sion according to size of study: in small studies there was no
difference between surgical studies and endovascular
studies, in larger studies, surgery was found to be superior
(p for interactionZ 0.005). Despite the detailed nature of
some of these analyses we acknowledge that the hetero-
geneity in the data extracted from these papers weaken
the evidence base and prevent us from drawing robust
conclusions.
Results
The selection processes yielded a total of 21 endovascular
and 21 surgical studies including a total of 4064 patients:
1750 endovascular patients in 16 prospective non-rando-
mised (PNRT) and 5 retrospective (RET) studies and 2314
surgical patients in 4 PNRTs and 17 RETs. Significant stenosis
was defined as being >50%, >60%, >70% and >75% in 5, 4, 9
and 1 endovascular papers and >50%, >60%, >70%, >75%,
and >80% in 2, 3, 1, 9 and 1 surgical papers respectively. 2
further surgical papers included only ‘high grade’ stenoses.
Age and co-morbidity
The first issue addressed was whether endovascular studies
included sicker and older patients. There was broad simi-
larity in age ranges across all the studies. Mean age was
67.8 years for endovascular, and 62.5 for surgical studies.
Mean maximum age was 83.6 years for endovascular and
79.4 years for surgical studies. Medians of the age ranges
Table 2 Co-morbidity data is similar across endovascular and surgical studies.
Co-morbidity Surgical papers Prevalence (%) Endovascular papers Prevalence (%)
Mean Median Mean Median
Ischaemic heart disease 12 53.4 52.9 15 59.9 60
Cerebrovascular disease 10 32.5 30 9 26.8 29
Diabetes 10 13.6 15 17 25.5 25.5
Peripheral vascular disease 13 58.7 56.4 13 48.6 48
Smoking 6 66 68.5 14 49.1 49.5
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however this data was not available most papers.
No data was available about the state of health of
patients at the time of intervention and the reporting of
co-morbidities varied among different papers. Nonetheless
distribution and prevalence of co-morbidities were similar
for both modalities (Table 2).
Follow-up
Difference in length of follow-upwasnotable.Meanof average
follow-up was 41.7 months (SD 27.5) in surgical and 15.3
months (SD 9.6) in endovascular studies. Time-points of
measurement of outcome data indicating effects on hyper-
tension and renal function however were not equivalent to
length of follow-up inmost of the papers. Themean timepoint
for endovascular papers was 7.1 months, median 6 months.
The mean time point for surgical papers was 25.1
months, median 22 months. This difference changes the
impact of the surgical outcome data such that surgical
outcomes pooled in this paper could be seen as sustained
long-term results. Combined time point and outcome data
including size of study population are shown in Fig. 1.
Technical success
Technical success was minimally but non-significantly lower
in surgical studies by 0.09% (95% CI: 0.62e0.80, pZ 0.8).
The surgical data however included the results of combined
renal and aortic procedures with those of isolated renal
revascularization.
Patency
This study was unable to compare maintenance of patency
beyond the initial technical success since there was insuffi-
cient patency data in surgical studies for analysis. 2 indi-
vidual papers quoted 98% and 92% patency at 36 and 60
months respectively. Patency data from 13 endovascular
papers were for the first year of follow-up with two further
papers quoting patency up to 36 months and one paper up to
60 months. Analysis of this data showed that stent patency
declined by 0.26% per month (95% CI: 0.04e0.48, pZ 0.03),
equivalent to a 3% absolute decrease in patency per year.
Survival
4 out of 26 endovascular papers supplied survival data
(Table 3), which was insufficient for analysis. 10 surgicalpapers supplied 5-year survival data ranging from 48 to 94%
(Fig. 2) and using denominators for each study, gave
a combined estimate of 68%.
Hypertension
There was a 21% higher rate of improvement in hyperten-
sion in surgical procedures compared to endovascular (95%
CI: 9e33%, pZ 0.001). The definitions of improvement
included normalization of blood pressure to diastolic pres-
sure 90 mmHg, a reduction in medications to maintain
diastolic pressure 90 mmHg, a reduction in diastolic
pressure by 15e20 mmHg or reduction in diastolic pressure
by 15%. Data for percentage improvement and deteriora-
tion are depicted in Fig. 1. Measurements were generally
taken at later time-points after surgical than after endo-
vascular procedures suggesting that improvement resulting
from surgical revascularization is sustained for longer
periods.
Differences between pre-procedural and immediate
post-procedural blood pressure have been simply presented
in Table 3 and Fig. 3a. The pre-procedural mean blood
pressures are similar in both the surgical and the endovas-
cular papers however there is a greater reduction in post-
procedural blood pressure in surgical papers.
These findings were further analysed to correct for
difference in study size and for variation in pre-procedural
blood pressure between the papers. This revealed a non-
significant 0.8% lower rate of deterioration in hypertension
in surgical procedures (95% CI: 0.7 to 2.2, pZ 0.28). A
weakly significant greater decrease in systolic pressure by
5 mmHg (95% CI: 3e12 mmHg, pZ 0.087) and diastolic by
4 mmHg (95% CI: 1e8 mmHg, pZ 0.012) was found, after
adjustment for pre-procedural blood pressures. The
difference in post-procedural MAP was 3.1 mmHg (95% CI:
1.0e7.3, pZ 0.13), being lower in the surgical group
after adjustment for pre-procedural MAP (Fig. 3a).
It is important to distinguish between describing
improvement in hypertension in terms of blood pressure
measurements and in terms of the applied definitions of
improvement in hypertension control which include
reduction in number of medications in addition to actual
pressure changes. Also, post-surgical blood pressure fluc-
tuates widely in response to inadequate pain control and
other noxious stimuli.
Renal function
There was a 34% higher rate of improvement in renal
function in surgical procedures compared to endovascular
Figure 1 Scatter-graphs of hypertension or renal function improvement (A), no change (B) and deterioration rates (C) against
average time-points of measurement for surgical (red circles) and endovascular (blue triangles) studies. The sizes of points are
proportional to study size. Longer surgical time-points suggest sustained longer-term outcome benefit.
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rate of deterioration in renal function in surgical proce-
dures (95% CI: 2.6e14.9, pZ 0.006). Definitions of
improvement in renal function varied. One surgical paper
required a 20% increase in eGFR (estimated Glomerular
Filtration rate) and 2 endovascular papers require a 15%
and 20% improvement in creatinine clearance respectively.
Remaining papers used serum creatinine levels as an
outcome measurement. Improvement was not defined in 13
papers. 11, 5 and 2 papers required a decrease in creatinineby 20%, 15% and 10% respectively. 3, 1 and 2 papers
required a decrease in creatinine of at least 17.5 mmol/L,
35 mmol/L and 80 mmol/L respectively.
To give another perspective, the difference between
pre-procedural and immediate post-procedural creatinine
levels is presented in Table 3 and Fig. 3b. It is immediately
evident that surgical papers studied populations with
worse renal function than endovascular papers and the
latter seem to have actually worsened renal function
overall.
Table 3 Pre-procedural blood pressure and serum creatinine measurements and poet-procedural reductions. The negative
value in creatinine reduction denotes a relative deterioration however average pre-op creatinine was higher in surgical papers.
Parameters assessed Surgical papers Endovascular papers
Mean Median SD Mean Median SD
Pre-op systolic BP (mmHg) 178.6 176.0 13 172.9 169 11.1
Reduction in systolic BP (mmHg) 33.0 34.0 13.8 23.0 19.3 15.9
Pre-op Diastolic BP (mmHg) 97.2 96.0 5.8 93.2 87.5 10.8
Reduction in diastolic BP (mmHg) 16.1 16.0 7.9 10.8 9.0 6.3
Pre-op MAP (mmHg) 123.0 121.7 9.9 119.3 116.5 9.0
Reduction in MAP (mmHg) 19.8 19.0 12.2 12.4 9.5 7.5
Pre-op creatinine (mmol/L) 259.4 239.0 71.4 158.1 150 29.6
Reduction in creatinine (mmol/L) 85.3 62.0 60 2.2 2.0 11.9
Figure 2 5-year mortality for surgical studies.
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analysed to correct for difference in study size and for
variation in pre-procedural blood pressure between the
papers. A significantly greater creatinine reduction of
54 mmol/L (95% CI: 28e80 mmol/L, p< 0.001) was found
after surgical treatment. The difference in post-procedural
creatinine was 32 mmol/L (95% CI: 7e57, pZ 0.014), being
lower in the surgical group, after adjustment for
pre-procedural creatinine.
Mortality
Initial comparison of mortality data showed a significant
3.1% excess procedure-related (30 day) mortality for
surgical treatment (95% CI: 1.8e4.4, p< 0.001). Excess
mortality denotes the average difference in mortality
between surgical and endovascular studies. Subsequent
inspection of the papers showed that several surgical
papers incorporated the results of more ambitious surgery
such as concurrent abdominal aortic aneurysm repair and
surgery for aortic occlusive disease which increase opera-
tive mortality. These procedures constituted 27.7% of total
surgical procedures. Isolated renal revascularization
included a variety of procedures: aorto-renal bypass with
vein or prosthetic grafts (23%), extra-anatomic bypass
(61%), endarterectomy patch angioplasty (14.6%) and bench
reconstruction and re-implantation (1.4%).
There was sufficient data to separate results for
combined aortic and renal procedures from isolated renal
artery revascularizations. Combined procedures conferred
a significant excess surgical mortality of 6.5% (95% CI:
3.8e9.3, p< 0.001) compared to isolated renal revascular-
ization Comparison of endovascular with isolated renal
artery surgical revascularization revealed an insignificant
0.18% excess mortality compared to endovascular mortality
(95% CI: 0.7e1.1, pZ 0.7) (Table 4).
Discussion
This analysis of the available data suggests that surgical
revascularization is a valuable treatment which has better
outcomes and durability than stent angioplasty. The
current limitation of surgery as a largely salvage measures
in technical failure of endovascular procedures can be
challenged by these results.
Figure 3 Graphs showing the pre- and post-procedural MAP (a) and serum creatinine (b) demonstrating advantage for surgical
studies and overall deterioration in post-procedural renal function in endovascular studies.
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with this analysis namely, the lack of high quality clinical
data to allow comparison of the two modalities. All
included studies are observational with variation in the
selection criteria of patients in different studies in terms of
severity of stenosis, renal length, renal function and
severity of hypertension. Additionally several publications
were excluded because the data were not accessible in
compatible format to allow analysis. We have presented
a pooled estimate of difference between surgical and
endovascular procedures for each outcome, to provide
a useful summary of this data from a large number of
studies from which to infer the relevant clinical importance
of surgical and endovascular renal revascularization.
During the time period covered by this study, there has
been progress in stent technology, pharmacology and non-
interventional management of ARAS. However there has
also been significant development in pre-operative cardio-
vascular optimization, selection, anaesthesia and peri-
operative management, making surgery a lower-risk option
in comparison to 15e30 years ago when most of these
surgical series were undertaken. The two major shortcom-
ings in studies investigating the outcomes of revasculari-
zation have consistently been a lack of long-term follow-upTable 4 Surgical mortality has been disadvantaged by the
inclusion of aortic aneurysm repair. The separate mortality
for surgical isolated renal revascularization is not signifi-
cantly higher than for endovascular procedures.
Increased
mortality
95% CI p value










0.18% 0.7e1.1Z0.70of patency and its correlation to changes in outcomes. It
has been increasingly recognized that revascularization of
a main stem renal artery does not improve outcomes when
there is irreversible end-organ dysfunction in the form of
atherosclerotic nephropathy and hypertensive nephro-
sclerosis. Prediction of renal parenchymal injury by
applying broad selection criteria such as renal length, limits
on serum creatinine levels and the presence or otherwise of
proteinuria have not yielded uniform outcome responses.
The use of renal biopsy for the diagnosis and scoring of
histopathological damage in atherosclerotic nephropathy
reported by Wright,7 showed consistent correlation
between scoring severity and renal functional prognosis.
This practice has not been widely adopted because of the
risk of damage to already compromised kidneys, additional
costs and the invasive nature of this procedure. One of the
outstanding findings in this paper is the difference in
improved outcomes in terms of hypertension control and
renal function after surgery despite the fact that these
improvements were measured at later time-points than in
endovascular studies. This also suggests that the benefits
from surgical outcomes are sustained for longer periods.
Endovascular revascularization is confirmed as giving less
functional improvement than expected from the excellent
technical success rates. The main theory to explain this
deficiency is atheroembolism from the considerable trauma
to the vessel walls both during catheterization and angio-
plasty and stenting. The recently introduced protection
devices still allow passage of showers of microemboli up to
100 mm in size, enough to block the glomerular pores which
are only 8 mm. Another possible phenomenon is the release
of tissue factor, other procoagulant inflammatory cytokines
and thrombin by the inflammatory response to the angio-
plasty procedure. Although these factors could also
complicate surgical revascularization, this procedure
requires the use of clamps and routine flushing of vessels to
remove any thrombus or particulate matter prior to
completion of an anastamosis, though clamping itself
potentially induces ischaemic injury. Yet another plausible
theory is the effect of the destruction of the sympathetic
innervations along the renal artery during surgical
dissection.
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concomitant aortic repair is excluded, no significant
difference in mortality was found between surgical and
endovascular repair. This lack of mortality benefit for
endovascular revascularization may be explained by case-
mix with higher risk patients selected for stent angioplasty
rather than surgery. Nevertheless, this analysis shows that
surgery focused purely on renal revascularization carries an
acceptably low operative mortality. Surgeons have several
options for revascularising the renal arteries which avoid
cross-clamping of the aorta such as aorto-renal bypass and
renal artery endarterectomy,8 where the aorta is side-
clamped, extra-anatomic bypass and rarely extra-corporeal
reconstruction with autotransplantation. The extra-
anatomical bypass is favoured by most surgeons because of
the subcostal incision with its lower morbidity and the
complete avoidance of the aorta.
This study shows that for suitable patients surgery could
be a significantly better option in terms of improved and
durable control of hypertension and improved renal func-
tion. However there is no Level 1 evidence to support this
conclusion. As a result of the almost universal preference
for stent angioplasty, vascular surgeons in the UK and much
of Europe are no longer a regular part of the clinical team
treating renovascular disease. This and the resultant
decrease in surgical expertise means that a prospective
randomised comparison of surgical and endovascular
revascularization is unlikely to happen. The results of our
analysis show that such a comparison is needed to defineFigure 4 Suggested algorithm for management of pthe roles of the two modalities in treating renovascular
disease. It is likely that the two modalities are compli-
mentary with stent angioplasty the treatment of choice in
sicker patients with a short life expectancy and surgical
reconstruction avoiding the aorta, the choice for younger,
fitter patients. We have already implied that the decision
process is complex and crucially depends on multi-disci-
plinary interaction to optimize outcomes. There is clearly
an important role for vascular surgery and based on the
results of this analysis we suggest an algorithm for the
management of patients with atherosclerotic renovascular
disease (Fig. 4). We recognise that this algorithm is not
based on unshakable Level 1 evidence however it may serve
as a guide in the clear absence of such evidence and would
be the ideal basis for a randomised controlled study espe-
cially if a medical arm was included.
Finally there is a lack of conclusive evidence that long-
term functional change and benefit are related to renal
artery patency. This is why management of asymptomatic
renal artery stenosis is primarily conservative/medical
management. On the other hand there is no evidence that
endovascular revascularization is superior to surgery in
maintaining patency. Moreover the general impression from
the findings of this study is that surgery is better for
patients in terms of functional outcome and that surgical
mortality, even from series carried out 15e30 years ago,
was already not significantly higher than that for endovas-
cular intervention. It is hoped that the findings from current
large trials will help to formulate clear guidelines foratients with atherosclerotic renovascular disease.
674 R. Abela et al.indications for revascularization and promote patency to be
re-addressed in future trials comparing the outcome of
endovascular and surgical intervention in patients who
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